Peptide Research Library

Source-labelled summaries for each product: how strong the evidence is, what the sources say, safety cautions and Australian legal status. Free, with no sign-up. It reports what research says. It does not recommend any product or dose.

Dosing, stacking and protocol details are not published here.

• Afamelanotide (peptide): main evidence human clinical trials. Australian legal status as of 2026-10-28.
• BPC-157 (peptide): main evidence small human studies. Australian legal status as of 2026-10-28.
• Bremelanotide (PT-141) (peptide): main evidence human clinical trials. Australian legal status as of 2026-10-28.
• Cagrilintide (peptide): main evidence human clinical trials. Australian legal status as of 2026-10-28.
• Calcitonin (peptide): main evidence human clinical trials. Australian legal status as of 2026-10-28.
• CJC-1295 (No DAC) (peptide): main evidence community reports. Australian legal status as of 2026-10-30.
• Dihexa (peptide): main evidence manufacturer information. Australian legal status as of 2026-10-30.
• DSIP (peptide): main evidence community reports. Australian legal status as of 2026-10-30.
• Dulaglutide (peptide): main evidence human clinical trials. Australian legal status as of 2026-10-28.
• Elamipretide (SS-31) (peptide): main evidence human clinical trials. Australian legal status as of 2026-10-28.
• Epitalon (peptide): main evidence community reports. Australian legal status as of 2026-10-30.
• Exenatide (peptide): main evidence human clinical trials. Australian legal status as of 2026-10-28.
• GHK-Cu (peptide): main evidence human clinical trials. Australian legal status as of 2026-10-28.
• Glucagon (peptide): main evidence human clinical trials. Australian legal status as of 2026-10-28.
• Insulin (peptide): main evidence human clinical trials. Australian legal status as of 2026-10-28.
• Larazotide (peptide): main evidence human clinical trials. Australian legal status as of 2026-10-28.
• Leuprolide (peptide): main evidence human clinical trials. Australian legal status as of 2026-10-28.
• Linaclotide (peptide): main evidence human clinical trials. Australian legal status as of 2026-10-28.
• Liraglutide (peptide): main evidence human clinical trials. Australian legal status as of 2026-10-28.
• Mazdutide (peptide): main evidence human clinical trials. Australian legal status as of 2026-10-28.
• Octreotide (peptide): main evidence human clinical trials. Australian legal status as of 2026-10-28.
• Oxytocin (peptide): main evidence small human studies. Australian legal status as of 2026-10-28.
• Pramlintide (peptide): main evidence human clinical trials. Australian legal status as of 2026-10-28.
• Retatrutide (peptide): main evidence human clinical trials. Australian legal status as of 2026-10-28.
• Semaglutide (peptide): main evidence human clinical trials. Australian legal status as of 2026-10-28.
• Sermorelin (peptide): main evidence small human studies. Australian legal status as of 2026-10-28.
• Survodutide (peptide): main evidence human clinical trials. Australian legal status as of 2026-10-28.
• TB-500 (peptide): main evidence animal studies. Australian legal status as of 2026-10-28.
• Teduglutide (peptide): main evidence human clinical trials. Australian legal status as of 2026-10-28.
• Teriparatide (peptide): main evidence human clinical trials. Australian legal status as of 2026-10-28.
• Tesamorelin (peptide): main evidence human clinical trials. Australian legal status as of 2026-10-28.
• Thymosin Alpha-1 (peptide): main evidence human clinical trials. Australian legal status as of 2026-10-28.
• Tirzepatide (peptide): main evidence human clinical trials. Australian legal status as of 2026-10-28.
• Vasopressin / desmopressin (peptide): main evidence human clinical trials. Australian legal status as of 2026-10-28.